工程化鞭毛蛋白佐剂增强重组RSV疫苗黏膜免疫
为应对RSV疫苗开发中的历史安全性顾虑(包括疫苗相关增强性呼吸道疾病VAERD),研究者理性设计了一种可溶性、稳定且去免疫化的鞭毛蛋白衍生佐剂FIC以激活黏膜免疫。在小鼠模型中,FIC佐剂的RSV预融合F(preF)疫苗诱导Th1偏向免疫应答,并增强上、下呼吸道攻击保护;鼻内序贯免疫优化了疫苗效力。
要点
- FIC佐剂联合RSV preF疫苗在小鼠中诱导Th1偏向免疫应答。
- 序贯免疫 regimens 含FIC可增强上、下呼吸道RSV攻击保护。
- 鼻内序贯免疫增强脾细胞抗原特异性细胞因子产生。
核心结论
- 结构导向的佐剂优化联合黏膜初免-加强策略可克服RSV疫苗学历史障碍,为呼吸道病原体疫苗开发提供路径。
研究设计与样本
- 小鼠模型研究,评估理性工程化的可溶性、稳定、去免疫化鞭毛蛋白衍生佐剂FIC搭配RSV preF疫苗。
主要发现
- FIC佐剂RSV preF疫苗诱导Th1偏向免疫应答,IFN-γ、IL-2、TNF-α表达升高。
- FIC佐剂疫苗诱导强健的pre-F特异性体液、细胞和黏膜免疫,同时最小化鞭毛蛋白相关免疫原性。
- 含FIC的序贯免疫方案显著增强对上、下呼吸道RSV攻击的保护。
- 鼻内序贯免疫增强脾细胞抗原特异性细胞因子产生,优化疫苗抗RSV效力。
临床怎么用
- 为RSV疫苗开发提供黏膜佐剂与序贯免疫策略的临床前依据。
局限性
- 证据来自小鼠模型,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory syncytial virus (RSV) infection is a global health concern that poses a significant threat to children under the age of five. Yet vaccine development has been hindered by historical safety concerns, including vaccine-associated enhanced respiratory disease (VAERD). To address these challenges, we rationally engineered a soluble, stable, and deimmunized flagellin-derived adjuvant (FIC) to activated mucosal immunity, which plays a critical role in protecting against respiratory diseases and is considered safe for children. In mouse models, FIC adjuvanted RSV prefusion F (preF) vaccines elicited a Th1-biased immune response, characterized by elevated expression levels of IFN-γ, IL-2, and TNF-α and robust pre-F-specific humoral, cellular, and mucosal immunity, while minimizing flagellin-associated immunogenicity. Further, a sequential immunization regimen incorporating FIC significantly enhanced protection against both upper and lower respiratory tract RSV challenges. Notably, intranasal sequential immunization enhanced antigen-specific cytokine production from splenocytes, thereby optimizing the vaccine's efficacy against RSV. These findings indicated that structure-guided adjuvant optimization combined with mucosal prime-boost strategies can overcome historical barriers in RSV vaccinology, offering a promising pathway for respiratory pathogen vaccine development.
引用
- Ye G, Qu C, Liao Z, et al. Engineered flagellin-based adjuvant boosts mucosal immunity in recombinant RSV vaccine. Vaccine. 2026. PMID: 41485249. doi:10.1016/j.vaccine.2025.128190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。